Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Free Cash Flow (2016 - 2025)

Cytosorbents (CTSO) has disclosed Free Cash Flow for 14 consecutive years, with -$2.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 0.8% year-over-year to -$2.6 million, compared with a TTM value of -$10.0 million through Sep 2025, up 46.73%, and an annual FY2024 reading of -$14.7 million, up 33.71% over the prior year.
  • Free Cash Flow was -$2.6 million for Q3 2025 at Cytosorbents, down from -$1.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$1.3 million in Q2 2025 and bottomed at -$10.3 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$4.8 million, with a median of -$4.9 million recorded in 2024.
  • The sharpest move saw Free Cash Flow plummeted 475.83% in 2021, then surged 73.06% in 2025.
  • Year by year, Free Cash Flow stood at -$7.0 million in 2021, then increased by 22.84% to -$5.4 million in 2022, then decreased by 19.99% to -$6.5 million in 2023, then skyrocketed by 62.94% to -$2.4 million in 2024, then decreased by 7.63% to -$2.6 million in 2025.
  • Business Quant data shows Free Cash Flow for CTSO at -$2.6 million in Q3 2025, -$1.3 million in Q2 2025, and -$3.7 million in Q1 2025.